| Objective:Cerebrovascular disease is one of the most common neurological diseases. The characteristics of its high paralysis and mortality rate seriously affect the quality of life of patients, and even threatening the lives of patients.. Currently, the key treatment of acute ischemic stroke:early intervention, outcome measures and increase the recovery rate and reduce the mortality rate, we should find new targets and produce effective drug treatment. This experiment will be through the change and the cerebral infarction area Hcy, hs-CRP level.The purpose of this study was to explore the protective role of Batroxobin and Edaravone on acute cerebral infarction and its possible mechanism; to explore the therapeutic effect of combined application of donlim Injection and edaravone on acute cerebral ischemia injury.Methods:Modified intraluminal middle cerebral artery occlusion (MCAO) model of cerebral ischemia reperfusion.Healthy adult male Wistar100rats, were randomly divided into five groups, sham operation group (normal group), batroxobin in treatment group, Edaravone group, Combined treatment group. Using histochemical staining technique, detection of cerebral infarction volume; by enzymatic cycling assay, detection of Hcy levels; by immune turbidimetry, changes of hs-CRP concentration detection.Result:1.Determination of cerebral ischemia and cerebral infarction in rats after24h comparison shows the volume:batroxobin group, edaravone group, combination group and ischemia reperfusion model group, both inhibited the volume of cerebral infarction.There was significant difference among groups (P<0.05); there were significant difference between combination group and edaravone group, batroxobin group,(P<0.05);2. Determination of Hcy:The ischemia reperfusion model group was significantly higher than that in normal group (P<0.05), batroxobin group was significantly lower than that of ischemia reperfusion model group (P<0.05), edaravone group was significantly lower than that of the ischemia reperfusion model group (P<0.05), batroxobin group was significantly lower than that of edaravone group (P<0.05), combination group was significantly lower than that of single drug group (P<0.05)3. Determination of high sensitivity C-reactive protein:The ischemia reperfusion model group was significantly higher than that in normal group (P<0.05), edaravone group was significantly lower than that of the ischemia reperfusion model group (P<0.05), batroxobin group was significantly lower than that of ischemia reperfusion model group (P<0.05), batroxobin group was significantly lower than that of edaravone group (P<0.05), combination group was significantly lower than single drug group (P<0.05).Conclusion:Tobishi batroxobin and edaravone can reduce the volume of acute cerebral infarction,and reducing the Hcy and ultra-sensitivity C-reactive protein levels,which can effectively reduce cerebral ischemic injury, has protective effect on brain. The treatment of acute cerebral infarction two drugs is only applied in treatment or edaravone Tobishi batroxobin its therapeutic effect is more significant. |
PDF Full Text Request